Ondansetron Eg

Ondansetron, the active ingredient in Ondansetron Eg, is a 5‑HT3 receptor antagonist presented as a strength/form for oral use. It treats nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adults and children. GNH USA supplies Ondansetron Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Ondansetron Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used to prevent and treat nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: Reduces the frequency and severity of nausea and vomiting caused by cytotoxic chemotherapy. - Radiation‑induced nausea and vomiting: Helps mitigate the nausea and vomiting that occurs during or after radiation therapy. - Post‑operative post‑operative nausea and vomiting (PONV): Decreases the incidence of nausea and vomiting following surgical procedures. - Pregnancy ?? -   -  -  -  - 

}]